Amazon RxPass: A Prescription For Profits?


  •, Inc. is–finally–leveraging its 2018 PillPack acquisition.
  • We expect that RxPass could, at very conservative 12-month estimates, add $600 million to Amazon’s top-line.
  • We believe that RxPass will provide the healthcare inroad that Amazon has been looking for.
Amazon prime boxes and envelopes delivered to a front door of residential building

Daria Nipot

The Doctor Will See You Now, Inc. (NASDAQ:AMZN) announced on Tuesday, January 24th, that it was rolling out the launch of new generic prescription drug service called RxPass. In this article, we’ll dive into why, unlike Amazon’s other forays into

Disclosure: I/we have a beneficial long position in the shares of AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Disclaimer: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Leave a Reply

Your email address will not be published. Required fields are marked *